Testing a new medication to slow lung scarring progression

Plain-English translation of NCT05139719 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This is a Phase IIb clinical trial testing HEC585, a new tablet medication, to see if it can slow the decline in lung function in patients with progressive fibrosing interstitial lung disease—a condition where lung tissue becomes increasingly scarred and stiff. The study will compare two different doses of the medication against a placebo (a pill with no active drug) to find out which works best and is safest. About 110 patients will participate.

Progressive fibrosing interstitial lung disease gets worse over time, with lung tissue becoming more scarred and making it harder to breathe. Current treatments don't work well enough for all patients, so researchers are testing this medication to see if it can slow that decline and give patients more time and better quality of life.

Do you qualify?

You likely qualify if…

you have progressive fibrosing interstitial lung disease (not idiopathic pulmonary fibrosis) that has been worsening over the past year
you have already tried standard lung disease treatments for at least 3 months
your lung function test (FVC) is at least 45% of what is expected for someone your size and age
you are 18 years or older and willing to follow the study requirements
you have clear signs of lung scarring on a chest CT scan covering more than 10% of your lungs
your carbon monoxide diffusion capacity is between 30% and 80% of normal

You likely don't qualify if…

you have been diagnosed with idiopathic pulmonary fibrosis (IPF)
you have significant heart failure or other serious heart problems related to your lung disease
you have had cancer in the past 5 years (except for minor skin cancers)
you are expected to receive a lung transplant during the study or have less than 6 months to live
you have other major lung or chest wall problems that would interfere with the study results

What participation looks like

If you join, you will take either the new medication or a placebo pill once daily for 24 weeks during the main study phase, then the option to continue for up to an additional 96 weeks in an extended phase. You will have regular clinic visits to monitor your lung function, take breathing tests, have chest imaging, and report how you are feeling. The study team will carefully track whether your lung function is staying stable and watch for any side effects.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Testing a new medication to slow lung scarring progression

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)